Holen Sie sich die Stockscreener-App
1.45
3.57%
0.05
Handel nachbörslich:
1.42
-0.03
-2.07%
Marker Therapeutics Inc Aktie (MRKR) Neueste Nachrichten
Marker Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline ProgressesMargin Compression Risk - Newser
Marker Therapeutics Inc. (MRKR) Q1 2026 Earnings: EPS Beat Expectations Amid Development Stage OperationsRevenue Estimate Trend - Newser
Marker Therapeutics Q1 2026 Earnings: Loss Narrows as Clinical Progress ContinuesPost-Earnings Drift - Newser
Marker Therapeutics (MRKR) upgraded to buy: What does it mean for the stock? - MSN
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Marker Therapeutics (MRKR) narrows Q1 2026 loss but warns on going concern - Stock Titan
Marker Therapeutics, Inc. Q1 2026: Net loss $(3.18M), Diluted EPS $(0.16) — 10-Q Summary - TradingView
MRKR: Net loss improved to $3.2M in Q1 2026, with cash funding expected through Q1 2027 - TradingView
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Marker Therapeutics (MRKR) Fell -0.82% — Is a Recovery Ahead? 2026-05-15Community Pattern Alerts - Newser
Marker Therapeutics (MRKR) Q4 2025 Earnings: $-0.09 EPS Surges Past $-0.20 EstimatesNew Analyst Coverage - Newser
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer - The Manila Times
TradingKey - TradingKey
Marker Therapeutics MRKR Q4 2025 loss narrows unexpectedly, beating estimates by 55%; shares tick higher.Crowd Entry Points - Newser
Number of shareholders of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
MSN Money - MSN
Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates - MSN
Marker Therapeutics (NASDAQ: MRKR) holders back share increase but reject voting change - Stock Titan
Pancreatic Cancer Pipeline Enters a New Era of Precision - openPR.com
Is Marker Therapeutics (MRKR) stock moving unpredictably (Ticks Down) 2026-04-24Safe Entry Stocks - newser.com
Is Marker Therapeutics (MRKR) stock worth buying today | Q4 2025: EPS Exceeds ExpectationsFinancial Data - Cổng thông tin điện tử tỉnh Lào Cai
Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02 - MSN
Stock List: Research Stocks from Around the World - GuruFocus
Ideas Watch: What are Marker Therapeutics Incs growth levers2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-04-06 22:29:12 - baoquankhu1.vn
Can Marker Therapeutics (MRKR) Stock Rebound in 2026 | Price at $1.44, Up 9.09%Expert Insights - Newser
Total debt per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
EBITDA per share of Marker Therapeutics, Inc. – FWB:GX1 - TradingView
Marker Therapeutics, Inc. (MRKR) stock price, news, quote and history - Yahoo Finance UK
EPS Watch: What is the long term forecast for Marker Therapeutics Inc stock2026 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Marker Therapeutics (MRKR) Stock Leading the Market | Price at $1.77, Up 1.14%Resistance Breakout Stocks - Newser
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
MRKR SEC FilingsMarker Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Sell: Can Marker Therapeutics Inc deliver consistent dividends2026 Fed Impact & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exit Recap: Should I hold or sell Marker Therapeutics Inc now2026 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday - Defense World
Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World
Q2 Earnings Estimate for MRKR Issued By Brookline Cap M - Defense World
Form DEF 14A Marker Therapeutics For: 20 March - Investing.com
Marker Therapeutics (NASDAQ: MRKR) proxy eyes 130M shares, lower vote hurdle - Stock Titan
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
[ARS] Marker Therapeutics, Inc. SEC Filing - Stock Titan
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones - TipRanks
Marker Therapeutics, Inc. 2025 10-K: Clinical-Stage Immuno-Oncology Pipeline, Regulatory Strategy, and Competitive Landscape Overview - Minichart
MARKER THERAPEUTICS, INC. (MRKR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Marker Therapeutics (MRKR) outlines MAR-T cancer pipeline, MT-601 trials and grant funding - Stock Titan
Marker Therapeutics 10-K: Revenue $3.55M; Net loss $12.18M - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):